Model: C57BL/6J mice, J20 mice, and 3xTg mice 
Dosage: 4.3 μEq l−1 of lithium in drinking water starting at 10 to 12 months of age and continued for 10 to 14 months during aging

Harvard Study: A Low Dose of Lithium May Preserve Cognitive Resilience with Age

Researchers uncover significantly lower brain lithium levels in Alzheimer’s disease patients, and supplementing with a low-dose lithium salt restores memory in an Alzheimer’s disease mouse model.

(The study’s principal investigator, Bruce Yankner [center], with four laboratory employees | The Boston Globe)

A Harvard study suggests lower levels of lithium in the brains of patients with Alzheimer’s disease and that lithium supplementation may help preserve cognitive resilience.

Brain &amp; Neurons

A high but not low dose of nattokinase is associated with reducing artery plaque size by 36% in older adults. 

An ultrasound of the carotid artery with arrows pointing to plaques (image: avicennacardiology.com). 

Cardiovascular

Model: Ten-month-old male EFAD mice 
Dosage: 14.4 ppm of alfatradiol in diet for five months

USC Study: Longevity-Promoting Drug Counteracts a Genetic Predisposition to Alzheimer's

The drug alfatradiol, also known as 17ɑ-estradiol, reduces cognitive errors on a test of memory and lowers neuronal plaques in mice genetically predisposed to Alzheimer’s disease.

(The University of Southern California | College Matchpoint)

Researchers unveil data suggesting the drug alfatradiol improves signs of frailty, reduces cognitive errors, and reduces neuronal plaques in mice with a genetic predisposition to Alzheimer’s disease.

Model: UM-HET3 mice and 5XFAD mice 
Dosage: UM=HET3 mice received 180 mg/kg canagliflozin in chow starting at seven months of age, and FXFAD mice received 180 mg/kg canagliflozin in chow beginning at three months of age

New Study: Diabetes Medication Improves Cognition and Alleviates Alzheimer’s Progression

The diabetes drug canagliflozin improves learning and memory in middle-aged male mice and reduces brain plaques in Alzheimer’s model mice.

The FDA-approved diabetes medication canagliflozin improves cognition in a mouse model of Alzheimer’s disease in males only.

Model: 8 adults with peripheral artery disease 
Dosage: 1,000 mg of NR daily for four weeks

New Study Suggests NR Modestly Improves Cognition in Age-Related Vascular Disease

Taking NR was associated with improved blood flow to a specific brain region following cognitive stimulation, as well as trends toward enhanced cognition in patients with age-related vascular disease.

(The study’s principal investigator, Andriy Yabluchanskiy | LinkedIn)

Taking NR is associated with improved blood perfusion to a brain region involved in memory and daily task organization, as well as a trend toward enhanced cognition.

Search Result: plaque

Harvard Study: A Low Dose of Lithium May Preserve Cognitive Resilience with Age

New Study Reveals: High-Dose Supplement Shrinks Arterial Plaque by 36%

USC Study Suggests Longevity-Promoting Drug Counteracts a Genetic Predisposition to Alzheimer’s

Diabetes Medication Improves Cognition and Alleviates Alzheimer’s Progression, Suggests New Study

New Study Suggests NR Modestly Improves Cognition in Human Subjects